Evidence map›Paper›PMID 34888221›Full record

ArticleAdvanced pharmaceutical bulletin2021

Assessment of the Effect of Infliximab on Immunomodulation Properties of Mesenchymal Stem Cells

Yasaman Aliasghari Sakha, Ehsan Ehsani, Elham Roshandel, Arsalan Jalili, Negar Vahdani, Abbas Hajifathali

Open access · diamondAbstract read
In one paragraph

Article in Advanced pharmaceutical bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Yasaman Aliasghari SakhaDevelopmental Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran.ORCID https://orcid.org/0000-0001-5611-5729
Ehsan EhsaniDepartment of Biology, Roudhen Branch, Islamic Azad University, Tehran, Iran.ORCID https://orcid.org/0000-0001-6148-0827
Elham RoshandelHematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Arsalan JaliliHematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Negar VahdaniHematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abbas HajifathaliHematopoietic Stem Cell Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-2191-0594
Islamic Azad University Roudehen Branch · IRShahid Beheshti University of Medical Sciences · IRIslamic Azad University, Science and Research Branch · IRRoyan Institute · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ImmunomodulationInfliximabMesenchymal stem cellsTumor necrosis factor

Identifiers

PMID34888221
PMCPMC8642797
OpenAlexW3089233936

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.